FDA warned CofixRx that its CofixRX Nasal Spray is an unapproved, misbranded drug sold with COVID-19 prevention claims.
What happened
On January 4, 2022, FDA reviewed the website cofixrx.com and the labeling on CofixRX Nasal Spray packaging. FDA found the non-alcohol-based antiseptic sold as intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions, with label and website claims such as destroying SARS-CoV-2 and cold and flu viruses in 15 seconds and lasting up to 8 hours. FDA said the product is an unapproved new drug and a misbranded drug.
What FDA found
CofixRX Nasal Spray is a new drug (a drug not generally recognized as safe and effective) sold without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product's label and website claims that it destroys SARS-CoV-2 and prevents cold and flu viruses make it a drug intended to prevent or treat disease.
section 201(g)(1)(B) and (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), (C)The product is misbranded because its labeling misleadingly suggests CofixRX is FDA approved.
section 502(a) of the FD&C Act, 21 U.S.C. 352(a)The product is misbranded because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee); section 505G, 21 U.S.C. 355hThe product does not conform to the applicable over-the-counter antiseptic tentative final monograph or other rule, including because it is intended for use inside the nostrils and makes time-specific efficacy claims.
section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h(a)(3); 1994 TFM, 59 FR 31402, as amendedIts introduction into interstate commerce is prohibited because it is an unapproved and misbranded drug.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a), (d)
What FDA wants
FDA tells CofixRx to take immediate action to stop selling unapproved and unauthorized COVID-19 products and to review its websites, labels, and promotional materials for misleading claims. Within 48 hours, the company must email the COVID-19 Task Force describing the steps taken to address the violations and prevent recurrence, or explain why it cannot do so and when it will.
Who should pay attention
- companies selling nasal antiseptic or COVID-19-related health products
- retailers and distributors of over-the-counter antiseptic products
- firms making antiviral or virus-prevention claims for non-drug products
This is a summary. Read the original letter on fda.gov.